Apixaban CAS 503612-47-3 Tsabtace ≥99.5% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. shine babban kamfani na Apixaban (CAS: 503612-47-3) tare da babban inganci.Ruifu Chemical na iya samar da isar da saƙo na duniya, farashi mai gasa, kyakkyawan sabis, ƙanana da adadi mai yawa akwai.Sayi Apixaban,Please contact: alvin@ruifuchem.com
| Sunan Sinadari | Apixaban |
| Makamantu | 1- (4-Methoxyphenyl) -7-oxo-6-[4- (2-oxopiperidin-1-yl) phenyl] -4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine -3-carboxamide, 4,5,6,7-Tetrahydro-1- (4-methoxyphenyl) -7-oxo-6-[4- (2-oxo-1-piperidinyl) phenyl] -1H-pyrazolo [3, 4-c] pyridine-3-carboxamide, BMS 562247, BMS-562247 |
| Matsayin Hannun jari | A Stock, Kasuwancin Kasuwanci |
| Lambar CAS | 503612-47-3 |
| Tsarin kwayoyin halitta | Saukewa: C25H25N5O4 |
| Nauyin Kwayoyin Halitta | 459.51 g/mol |
| Matsayin narkewa | 235.0 ~ 238.0 ℃ |
| Yawan yawa | 1.42 |
| COA & MSDS | Akwai |
| Asalin | Shanghai, China |
| Kashi | API |
| Alamar | Ruifu Chemical |
| Abubuwa | Ka'idojin dubawa | Sakamako |
| Bayyanar | Fari zuwa Kashe-White Crystalline Foda | Ya bi |
| Asara akan bushewa | ≤0.50% | 0.10% |
| Ragowa akan Ignition | ≤0.10% | 0.08% |
| Karfe masu nauyi (kamar Pb) | ≤20ppm | Ya bi |
| Abubuwa masu alaƙa | ||
| Duk Wani Rashin Tsabtace Guda Daya | ≤0.50% | Ya bi |
| Jimlar ƙazanta | ≤0.50% | Ya bi |
| Tsarkake / Hanyar Bincike | ≥99.5% (HPLC) | 99.9% |
| Infrared Spectrum | Yayi daidai da Tsarin | Ya bi |
| 1 H NMR Spectrum | Yayi daidai da Tsarin | Ya bi |
| Kammalawa | An gwada samfurin kuma ya dace da ƙayyadaddun bayanai | |
Kunshin:Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye akwati sosai kuma a adana a wuri mai sanyi, bushe (2 ~ 8 ℃) da ma'ajin da ke da isasshen iska daga abubuwan da ba su dace ba.Kare daga haske da danshi.
Jirgin ruwa:Isar da shi zuwa duniya ta iska, ta FedEx / DHL Express.Bayar da isarwa cikin sauri kuma abin dogaro.
Babu ɗaya daga cikin samfurin da za a kawo wa ƙasashen da wannan zai iya yin rikici da haƙƙin mallaka.Koyaya, alhakin ƙarshe yana kan mai siye.
Don binciken kimiyya kawai amfani, ba don kowane dalili na kasuwanci ba, ba don amfanin mutum ko bincike ba.
Yadda ake siya?Da fatan za a tuntuɓiDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Kwarewar Shekaru 15?Muna da fiye da shekaru 15 na gwaninta a cikin ƙira da fitarwa na matsakaicin matsakaicin magunguna masu inganci ko sinadarai masu kyau.
Manyan Kasuwanni?Sayarwa zuwa kasuwannin cikin gida, Arewacin Amurka, Turai, Indiya, Koriya, Jafananci, Australia, da sauransu.
Fa'idodi?Babban inganci, farashi mai araha, sabis na ƙwararru da tallafin fasaha, bayarwa da sauri.
inganciTabbaci?Tsananin kula da ingancin inganci.Kayan aikin ƙwararru don bincike sun haɗa da NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, gwajin ƙayyadaddun ƙwayoyin cuta, da sauransu.
Misali?Yawancin samfurori suna ba da samfurori kyauta don ƙima mai kyau, farashin jigilar kaya ya kamata a biya ta abokan ciniki.
Binciken Masana'antu?Ma'aikata duba maraba.Da fatan za a yi alƙawari a gaba.
MOQ?Babu MOQ.Karamin tsari abin karɓa ne.
Lokacin Bayarwa? Idan cikin hannun jari, garantin isar da kwana uku.
Sufuri?By Express (FedEx, DHL), ta Air, ta Teku.
Takardu?Bayan sabis na tallace-tallace: COA, MOA, ROS, MSDS, da dai sauransu za a iya ba da su.
Haɗin Kan Al'ada?Zai iya ba da sabis na haɗawa na al'ada don dacewa da buƙatun bincikenku.
Sharuɗɗan Biyan kuɗi?Za a fara aiko da daftari na Proforma bayan tabbatar da oda, an rufe bayanan bankin mu.Biya ta T/T (Telex Transfer), PayPal, Western Union, da dai sauransu.
Apixaban (CAS: 503612-47-3) wani sabon nau'i ne na maganin maganin jini na baka wanda Bristol Myers Squibb da Pfizer suka haɓaka.Wani sabon nau'i ne na mai hana factor Xa na baka, kuma sunansa na kasuwanci shine Eliquis.Ana amfani da Apixaban don kula da tsofaffi marasa lafiya da ke fuskantar zaɓaɓɓen hip ko gwiwa don hana thromboembolism venous (VTE)
Apixaban (CAS: 503612-47-3) wani zaɓi ne na baka wanda aka kunna Xa factor inhibitor kuma yana iya hana haɓakar thrombin da thrombosis.
Apixaban (CAS: 503612-47-3) shine na uku sabon maganin maganin ciwon baki da za a ci gaba da siyarwa, bayan dabigatran da rivaroxaban, kuma an riga an amince da shi a Turai don hana thromboembolism na jijiyoyi a cikin marasa lafiya da ke fuskantar zaɓen hip ko gwiwa.Daga cikin waɗannan magungunan guda uku na baka da aka amince da su a Turai, idan aka kwatanta da daidaitattun maganin rigakafi na yanzu game da thromboembolism venous, enoxaparin, rivaroxaban sun yi fice a gwajin rikodin, kuma apixaban sun yi fice a gwajin gaba.Hanyoyin warkewar Rivaroxaban sun ɗan fi girma, amma ya haifar da zub da jini mai tsanani fiye da apixaban.Masu bincike sun danganta waɗannan bambance-bambancen zuwa lokacin magani, kamar yadda aka ɗauki rivaroxaban sa'o'i 6-8 bayan tiyata a cikin gwajin rikodin, yayin da aka yi amfani da apixaban sa'o'i 18 bayan tiyata a gwajin gaba.Waɗannan magungunan suna da mafi kyawun maganin warkewa lokacin amfani da su kusa da lokacin tiyata, amma kuma suna da haɗarin zubar jini.Binciken asibiti ya nuna cewa idan aka kwatanta da allurar subdermal na yau da kullun na 40mg enoxaparin, 2 na baka na 2.5mg na apixaban yana da mafi kyawun rigakafin rigakafin cutar thromboembolism bayan tiyatar maye gurbin hip ko gwiwa kuma bai ƙara haɗarin zubar jini ba.
Apixaban (CAS: 503612-47-3) wani sabon nau'i ne na mai hanawa Xa factor inhibitor tare da Bristol-Myers Squibb da Pfizer suka haɓaka.Sunan ciniki shine eratol, wanda shine sabon nau'in maganin maganin jini na baka.Ta hanyar hana wani muhimmin coagulation factor Xa, apixaban zai iya hana thrombin samar da thrombosis.A ranar 26 ga Afrilu, 2007, Bristol-Myers Squibb ya haɗa hannu tare da Pfizer don sanar da haɗin gwiwa a cikin haɓaka sabon apixaban na maganin ciwon zuciya mallakar Bristol-Myers Squibb a matsayin ingantaccen madadin warfarin.Bisa yarjejeniyar haɗin gwiwa, Pfizer zai biya bashin dalar Amurka biliyan 0.25 ga Bristol-Myers Squibb don ɗaukar kashi 60% na jimlar ci gaban apixaban anticoagulant (wanda za a aiwatar daga Janairu 1, 2007), yayin da Bristol-Myers Squibb zai ɗauki sauran 40%, don haka samun haƙƙin haɓakawa da sayar da magani tare.A cikin watan Mayu 2011, apixaban shine farkon wanda ya amince da rigakafin cututtukan jijiyoyi a cikin manya marasa lafiya da ke fuskantar zaɓaɓɓen hip ko gwiwa a cikin ƙasashen EU na 27, Iceland da Norway.A ranar 20 ga Nuwamba, 2012, Hukumar Tarayyar Turai ta amince da Ererto (apixaban) don rigakafin bugun jini da bugun jini a cikin tsofaffi marasa lafiya tare da ƙananan ƙwayoyin cuta (NVAF) tare da ɗaya ko fiye da abubuwan haɗari.Daga baya, Hukumar Abinci da Magunguna ta Kanada, Japan, da FDA ta Amurka sun amince da Ererto?(apixaban) don rigakafin bugun jini da bugun jini a cikin manya marasa lafiya tare da fibrillation na valvular (NVAF) tare da abubuwan haɗari ɗaya ko fiye.A ranar 12 ga Afrilu, 2013, an ba da sanarwar cewa za a jera sabon magani na Eloto (ELIQUIS) (apixaban) tare da haɗin gwiwar Bristol-Myers Squibb da Pfizer a cikin kasar Sin.Ererto wani labari ne na baka na Xa inhibitor don rigakafin thromboembolism venous (VTE) a cikin manya marasa lafiya da ke fuskantar zaɓen hip ko gwiwa.Jerin sa yana ba da sabon zaɓi mai aminci kuma mai inganci don maganin ƙwanƙwasawa na asibiti bayan tiyatar orthopedic, kuma yana kawo labari mai daɗi ga majinyatan Sinawa waɗanda ke fuskantar maye gurbin hip/ gwiwa.Nazarin asibiti sun tabbatar da cewa idan aka kwatanta da 40mg enoxaparin sau ɗaya a rana, sau 2 a rana ta baka na eratol?(apixaban) 2.5mg ya fi tasiri don hana thromboembolism venous bayan tiyata maye gurbin hip ko gwiwa, kuma baya ƙara haɗarin zubar jini.Hoto 1 yana nuna allunan Elotoapixaban wanda Bristol-Myers Squibb da Pfizer suka samar.
![Apixaban Intermediate CAS 27143-07-3 Ethyl Chloro [(4-Methoxyphenyl) hydrazono] acetate tsarki ≥99.0% (HPLC)](https://www.ruifuchemical.com/uploads/Apixaban-Intermediate-CAS-490-46-0-Factory-Shanghai-Ruifu-Chemical-Co.-Ltd.-www.ruifuchem.com_-300x300.jpg)
